Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
Two doses of chiglitazar cut liver fat far more than a placebo in 18 weeks
In a phase II randomized, double-blind, placebo-controlled trial, 104 patients with MASLD, hypertriglyceridemia, and insulin resistance rece…
Patients with fatty liver disease and high triglycerides saw liver fat drop significantly with chiglitazar compared to placebo after 18 week…
Oral Sodium Butyrate Reduces Weight in Overweight Adults Without Diabetes
Oral sodium butyrate helps overweight adults without diabetes lose weight
This 12-week proof-of-concept RCT in 46 overweight adults (23 with type 2 diabetes) found that oral sodium butyrate 1875 mg/day led to great…
A new trial shows oral sodium butyrate helps adults without diabetes lose more weight than a placebo over three months.
Glenzocimab fails to improve outcomes in acute ischemic stroke thrombolysis
New stroke drug shows no benefit for patients treated with clot-busting therapy
This phase 2/3 randomized trial tested glenzocimab versus placebo in 421 patients with acute ischemic stroke treated by thrombolysis. The pr…
A major trial found that glenzocimab did not improve long-term disability scores for stroke patients who received standard clot-busting trea…
Essential phospholipids reduced hepatic steatosis and improved HbA1c in patients with MASLD and type 2 diabetes over 6 months.
Essential Phospholipids Reduce Liver Fat In Six Months
This randomised, placebo-controlled phase 4 trial enrolled 193 patients with metabolic dysfunction-associated steatotic liver disease and ty…
Essential phospholipids may lower liver fat and improve energy levels for people with fatty liver disease and diabetes within just six month…
Memantine improved neuropathy severity and pain scores versus placebo in CIPN over eight weeks.
Memantine eased nerve pain and tingling for chemotherapy patients in eight weeks
This randomized clinical trial enrolled 176 individuals with chemotherapy-induced peripheral neuropathy. Participants received memantine or …
A new trial found memantine significantly reduced nerve pain and tingling in chemotherapy patients compared to placebo over eight weeks.
Semaglutide high dose for weight reduction in people with Type 2 Diabetes
New drug helps obese diabetics lose weight and control sugar
This randomized controlled trial in 512 people with excess weight and Type 2 Diabetes compared high-dose semaglutide to placebo and lower do…
New research shows a specific injection helps people with obesity and diabetes lose weight and control their blood sugar levels better than …
Modified Banxia Xiexin Decoction plus chemotherapy shows favorable trends in advanced colorectal cancer.
Modified herbal decoction may extend survival time for advanced colorectal cancer patients
This randomized controlled trial in 129 patients with advanced colorectal cancer evaluated modified Banxia Xiexin Decoction (mBXD) granules …
Adding a modified herbal decoction to standard cancer treatment might extend survival time and reduce tumor growth in patients with advanced…
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial
High Inflammation Might Reduce Placebo Effect in Cancer
This exploratory analysis of an RCT in 45 cancer patients with dyspnea found a negative association between baseline cytokine levels and sym…
Scientists found that high inflammation levels may stop the placebo effect from working well.
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial.
New Drug Cuts Weight by Nearly 20% in Just 35 Weeks
In this randomized, placebo-controlled phase 1b/2a trial, 60 Chinese adults with overweight or obesity received GZR18 or placebo. Over 26 to…
This new treatment shows huge promise for helping people reach their weight goals without daily pills.
Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults.
Common Heart Flutters May Be Linked to Brain Drug
In this Phase 2 randomized, double-blind, placebo-controlled trial of 241 symptomatic adults with frequent PACs (≥1000/24 h), memantine show…
A new study shows a brain medication may calm frequent heart flutters and lower the risk of more serious heart rhythm problems.